50794-15-5

Upstream product

• 623-33-6 glycine ethyl ester hydrochloride 
• 612-23-7 2-nitrobenzyl chloride 
• 3958-60-9 2-nitrophenylmethyl bromide 
• 459-73-4 GlyOEt*HCl 
• 552-89-6 2-nitro-benzaldehyde 

Downstream Products

• 145629-21-6 [(5-Chloro-6-hydroxy-benzofuran-2-carbonyl)-(2-nitro-benzyl)-amino]-acetic acid 
• 145629-22-7 [(6-Acetoxy-5-chloro-benzofuran-2-carbonyl)-(2-nitro-benzyl)-amino]-acetic acid 
• 145629-25-0 Acetic acid 5-chloro-2-[(methoxycarbamoyl-methyl)-(2-nitro-benzyl)-carbamoyl]-benzofuran-6-yl ester 
• 85061-59-2 2-amino-1-(o-aminobenzyl)-2-imidazolin-4-one 
• 85061-53-6 2-Amino-1-(2-nitro-benzyl)-1,5-dihydro-imidazol-4-one; hydrochloride 
• 407623-08-9 4-(4-chlorobenzoyl)-1,3,4,5-tetrahydrobenzo-[e][1,4]diazepin-2-on 
• 179686-66-9 tert-butyl 2-oxo-1,2,3,5-tetrahydro-4H-1,4-benzodiazepine-4-carboxylate 
• 407623-40-9 1-[4-(2,5-dihydro-1H-pyrrol-1-ylcarbonyl)benzyl]-1,3,4,5-tetrahydrobenzo[e][1,4]diazepin-2-on monohydrochloride 

Relevant academic research and scientific papers

NRF2 REGULATORS

Provided are aryl analogs，pharmaceutical compositions containing them and their use as NRF2 regulators.

THERAPEUTIC AGENT FOR URINARY INCONTINENCE

PROBLEM TO BE SOLVED: To provide a new higher safe compound having higher effectiveness against urinary incontinence with smaller adverse effects. SOLUTION: A prophylactic and/or therapeutic agent for the urinary incontinence comprises a compound represented by formula (I) {wherein, A is a single bond or methylene; E and G are each a lower straight-chain alkylene which may be substituted with a lower alkyl; m is 0-5; R1s are each a halogen, a CF3, an OCF3, a CN, an NO2, a carboxy, an OH, an SH, a lower alkoxycarbonyl, a (substituted) carbamoyl, a lower alkanoyloxy, a (substituted) sulfamoyl group or a lower alkyl group or the like which may be substituted with an ORa (wherein, Ra is an H or a lower alkyl), a COORa, an SRa or an N(Ra)2; R2, R3 and R4 are each an H or a lower alkyl; n is 0-5; R5s are each a CN, an NO2, a COOH, an SO3H, a lower alkoxycarbonyl, a lower alkanoyl or the like; R6 and R7 are each an H or a lower alkyl which may be substituted with an ORa or a COOH; or an NR6R7 is a 5- to a 6-membered saturated heterocyclic ring}, an optically active substance or a pharmacologically acceptable salt thereof as an active ingredient. The drug exhibits excellent effects on treatment and/or prophylaxis of the urinary incontinence without causing adverse effects on the cardiovacular system such as blood pressure elevation.

Benzodiazepine derivatives

The present invention provides benzodiazepine derivatives of the following formula, analogs thereof and pharmaceutically acceptable salts thereof. The compounds of the present invention have an excellent effect of inhibiting activated blood-coagulation factor X. These compounds are usable as agents for treating various diseases concerned with the activated blood-coagulation factor X.

1,5-Dihydroimidazoquinazolinones as blood platelet aggregation inhibitors

Syntheses of 1,5-dihydroimidazoquinazolinones and their activities as blood platelet aggregation inhibitors are described.